Review



01 6 staphylococcus aureus atcc  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC 01 6 staphylococcus aureus atcc
    01 6 Staphylococcus Aureus Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 4059 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/01 6 staphylococcus aureus atcc/product/ATCC
    Average 99 stars, based on 4059 article reviews
    01 6 staphylococcus aureus atcc - by Bioz Stars, 2026-04
    99/100 stars

    Images



    Similar Products

    01 6 staphylococcus aureus atcc  (ATCC)
    99
    ATCC 01 6 staphylococcus aureus atcc
    01 6 Staphylococcus Aureus Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/01 6 staphylococcus aureus atcc/product/ATCC
    Average 99 stars, based on 1 article reviews
    01 6 staphylococcus aureus atcc - by Bioz Stars, 2026-04
    99/100 stars
    		  Buy from Supplier
    i57n a247e ssm 6 01 atcc  (ATCC)
    99
    ATCC i57n a247e ssm 6 01 atcc
    Molecular genetic characterization of laboratory-generated S. aureus mutants with decreased susceptibility to REP8839
    I57n A247e Ssm 6 01 Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/i57n a247e ssm 6 01 atcc/product/ATCC
    Average 99 stars, based on 1 article reviews
    i57n a247e ssm 6 01 atcc - by Bioz Stars, 2026-04
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Molecular genetic characterization of laboratory-generated S. aureus mutants with decreased susceptibility to REP8839

    Journal:

    Article Title: Mode of Action and Biochemical Characterization of REP8839, a Novel Inhibitor of Methionyl-tRNA Synthetase

    doi: 10.1128/AAC.49.10.4253-4262.2005

    Figure Lengend Snippet: Molecular genetic characterization of laboratory-generated S. aureus mutants with decreased susceptibility to REP8839

    Article Snippet: No mutants with MICs of >32 μg/ml were observed. table ft1 table-wrap mode="anchored" t5 TABLE 5. caption a7 Isolation method Isolate(s) Parental strain (phenotype a ) MIC (μg/ml) MetS mutation(s) Spontaneous resistance SSM5, others (25 isolates) ATCC 29213 4-8 157N SR5-1; SR5-2 ATCC 43300 (MRSA) 8 157N FSM 9, others (6 isolates) 87-2797 (MRSA, HL-MupR) 4-16 I57N SR23-1 LZ10 (MRSA) 8 I57N SR59-1, SR59-2 1079077 (MRSA) 8 I57N SR74-2 MB000193 (MRSA) 8 I57N SR3, SR18, SR21 ATCC 29213 16-32 G54S FSM7 87-2797 (MRSA, HL-MupR) 16 G54S SR74-1 MB000193 (MRSA) 16 G54S SR84-1, SR84-2 MB000057 (MRSA) 16 G54S SR23-2 LZ10 (MRSA) 32 G54S SR19, SR23 ATCC 29213 0.5-1 None FSM8 87-2797 (MRSA, HL-MupR) 1 None Serial passage SP-1B5, SP-2D4, others (8 isolates) ATCC 29213, ATCC 43300, others 8-16 I57N SP-21C 31-1334 (MRSA, LL-MupR) 8 I57T SP-27H 10-420 (MRSA, HL-MupR) 4 E52D SP-27D 14-354 (MRSA, LL-MupR) 2 A61V SP-21A ATCC 29213 4 A77V SP-25G LZ6 (MRSA, HL-MupR) 8 V108M SP-2C4 ATCC 43300 (MRSA) 2 L213W SP-28B 25-670 (MRSA, HL-MupR) 4 V215A SP-4A2 87-2797 (MRSA, HL-MupR) 8 G223C SP-11A3 31-1334 (MRSA, LL-MupR) 8 1238F SP-1A2 ATCC 29213 4 A247E SP-9B5 ATCC 29213 4 I57N V296F SP-2B5 ATCC 43300 (MRSA) 32 I57N R100S SP-4B5 87-2797 (MRSA, HL-MupR) 32 I57N V242F SP-25C 31-1334 (MRSA, LL-MupR) 2 T50A V242I SP-26C 1079101 (HL-MupR) 32 G54A A64P SP-25F LZ1 (MRSA, HL-MupR) 16 A61T A64S SP-22B 25-670 (MRSA, HL-MupR) 8 A61T V108L SP-21G LZ6 (MRSA, HL-MupR) 2 I94N V215A SP-21H 10-420 (MRSA, HL-MupR) 8 V215I V242F SP-22C 1079101 (HL-MupR) 16 L19F Q58L A64P SP-25D 14-354 (MRSA, LL-MupR) 8 A61T E98G M269I SP-26B 25-670 (MRSA, HL-MupR) 4 P230T A247E L257P SP-21B ATCC 43300 (MRSA) 2 None SP-3A5 31-1334 (MRSA, LL-MupR) 2 None SP-4D5 87-2797 (MRSA, HL-MupR) 0.25 None Second-step mutations SSM 1-01, SSM 1-02, SSM 1-03 ATCC 29213 32 I57N A247E SSM 6-01 ATCC 29213 32 I57N G54S SSM 6-02, 6-03 ATCC 29213 32 I57N I238F SSM 14-01, 14-02 LZ6 (MRSA, HL-MupR) 32 G54S V108M Open in a separate window a HL-MupR, high-level mupirocin resistant; LL-MupR, low-level mupirocin resistant.

    Techniques: Mutagenesis

    Fitness burden due to MetS mutations. Wild-type cells were grown in competition cocultures with SP-1A2 cells (MetS with A247E) (A) or with SR3 cells (MetS with G54S) (B). Diluted samples were plated on blood agar to enumerate total cells or on selective agar containing REP8839 to enumerate MetS mutant cells. Increased ratios of wild-type cells to MetS mutant cells in the mixed cultures illustrate the varying cost of fitness (C).

    Journal:

    Article Title: Mode of Action and Biochemical Characterization of REP8839, a Novel Inhibitor of Methionyl-tRNA Synthetase

    doi: 10.1128/AAC.49.10.4253-4262.2005

    Figure Lengend Snippet: Fitness burden due to MetS mutations. Wild-type cells were grown in competition cocultures with SP-1A2 cells (MetS with A247E) (A) or with SR3 cells (MetS with G54S) (B). Diluted samples were plated on blood agar to enumerate total cells or on selective agar containing REP8839 to enumerate MetS mutant cells. Increased ratios of wild-type cells to MetS mutant cells in the mixed cultures illustrate the varying cost of fitness (C).

    Article Snippet: No mutants with MICs of >32 μg/ml were observed. table ft1 table-wrap mode="anchored" t5 TABLE 5. caption a7 Isolation method Isolate(s) Parental strain (phenotype a ) MIC (μg/ml) MetS mutation(s) Spontaneous resistance SSM5, others (25 isolates) ATCC 29213 4-8 157N SR5-1; SR5-2 ATCC 43300 (MRSA) 8 157N FSM 9, others (6 isolates) 87-2797 (MRSA, HL-MupR) 4-16 I57N SR23-1 LZ10 (MRSA) 8 I57N SR59-1, SR59-2 1079077 (MRSA) 8 I57N SR74-2 MB000193 (MRSA) 8 I57N SR3, SR18, SR21 ATCC 29213 16-32 G54S FSM7 87-2797 (MRSA, HL-MupR) 16 G54S SR74-1 MB000193 (MRSA) 16 G54S SR84-1, SR84-2 MB000057 (MRSA) 16 G54S SR23-2 LZ10 (MRSA) 32 G54S SR19, SR23 ATCC 29213 0.5-1 None FSM8 87-2797 (MRSA, HL-MupR) 1 None Serial passage SP-1B5, SP-2D4, others (8 isolates) ATCC 29213, ATCC 43300, others 8-16 I57N SP-21C 31-1334 (MRSA, LL-MupR) 8 I57T SP-27H 10-420 (MRSA, HL-MupR) 4 E52D SP-27D 14-354 (MRSA, LL-MupR) 2 A61V SP-21A ATCC 29213 4 A77V SP-25G LZ6 (MRSA, HL-MupR) 8 V108M SP-2C4 ATCC 43300 (MRSA) 2 L213W SP-28B 25-670 (MRSA, HL-MupR) 4 V215A SP-4A2 87-2797 (MRSA, HL-MupR) 8 G223C SP-11A3 31-1334 (MRSA, LL-MupR) 8 1238F SP-1A2 ATCC 29213 4 A247E SP-9B5 ATCC 29213 4 I57N V296F SP-2B5 ATCC 43300 (MRSA) 32 I57N R100S SP-4B5 87-2797 (MRSA, HL-MupR) 32 I57N V242F SP-25C 31-1334 (MRSA, LL-MupR) 2 T50A V242I SP-26C 1079101 (HL-MupR) 32 G54A A64P SP-25F LZ1 (MRSA, HL-MupR) 16 A61T A64S SP-22B 25-670 (MRSA, HL-MupR) 8 A61T V108L SP-21G LZ6 (MRSA, HL-MupR) 2 I94N V215A SP-21H 10-420 (MRSA, HL-MupR) 8 V215I V242F SP-22C 1079101 (HL-MupR) 16 L19F Q58L A64P SP-25D 14-354 (MRSA, LL-MupR) 8 A61T E98G M269I SP-26B 25-670 (MRSA, HL-MupR) 4 P230T A247E L257P SP-21B ATCC 43300 (MRSA) 2 None SP-3A5 31-1334 (MRSA, LL-MupR) 2 None SP-4D5 87-2797 (MRSA, HL-MupR) 0.25 None Second-step mutations SSM 1-01, SSM 1-02, SSM 1-03 ATCC 29213 32 I57N A247E SSM 6-01 ATCC 29213 32 I57N G54S SSM 6-02, 6-03 ATCC 29213 32 I57N I238F SSM 14-01, 14-02 LZ6 (MRSA, HL-MupR) 32 G54S V108M Open in a separate window a HL-MupR, high-level mupirocin resistant; LL-MupR, low-level mupirocin resistant.

    Techniques: Mutagenesis